Novavax’s Covid-19 vaccine was highly effective in preventing symptomatic infections, hospitalizations, and severe illnesses, long-awaited results from the company’s Phase 3 trial, released Monday, revealed. The vaccine was 90% protective against laboratory-confirmed symptomatic infection. The trial results put this vaccine in the same efficacy ballpark as the mRNA vaccines produced by Pfizer-BioNTech and Moderna. But where those companies are currently producing and selling hundreds of millions of doses and are in the process of seeking full licensure from the FDA, Novavax still has steps it must take before it can apply for the regulatory authorizations it will need to start rolling out its vaccine.